E-LIB Suche - Ergebnisse für: Hanley, Michael

1

Evaluation of the drug–drug interaction potential of brigat..:

Hanley, Michael J. ; Yeo, Karen Rowland ; Tugnait, Meera...
CPT: Pharmacometrics & Systems Pharmacology. 13 (2024) 4 - p. 624-637 , 2024

Link: https://doi.org/10.1002/..

2

A phase 1 study to assess the absolute bioavailability, mas..:

Hanley, Michael J. ; Zhang, Steven ; Griffin, Robert...
Investigational New Drugs. , 2024

Link: https://doi.org/10.1007/..

3

Mobocertinib: Mechanism of action, clinical, and translatio..:

Hanley, Michael J. ; Camidge, D. Ross ; Fram, Robert J..
Clinical and Translational Science. 17 (2024) 3 - p. , 2024

Link: https://doi.org/10.1111/..

4

Response‐Based Dosing for Ponatinib: Model‐Based Analyses o..:

Hanley, Michael J. ; Diderichsen, Paul ; Rich, Benjamin...
Clinical Pharmacology & Therapeutics. 114 (2023) 2 - p. 413-422 , 2023

Link: https://doi.org/10.1002/..

5

Phase I Study of Entinostat, Atezolizumab, Carboplatin, and..:

Gentzler, Ryan D ; Villaruz, Liza C ; Rhee, John C...
The Oncologist. 28 (2023) 11 - p. 1007-e1107 , 2023

Link: https://doi.org/10.1093/..

6

Brigatinib pharmacokinetics in patients with chronic hepati..:

Hanley, Michael J. ; Kerstein, David ; Tugnait, Meera...
Investigational New Drugs. 41 (2023) 3 - p. 402-410 , 2023

Link: https://doi.org/10.1007/..

7

Dose Titration of Ixazomib Maintenance Therapy in Transplan..:

Srimani, Jaydeep K. ; Diderichsen, Paul M. ; Hanley, Michael J...
Clinical Pharmacology & Therapeutics. 114 (2023) 1 - p. 220-229 , 2023

Link: https://doi.org/10.1002/..

8

A Phase 1 Drug‐Drug Interaction Study Between Brigatinib an..:

Hanley, Michael J. ; D'Arcangelo, Manolo ; Felip, Enriqueta...
The Journal of Clinical Pharmacology. 63 (2023) 5 - p. 583-592 , 2023

Link: https://doi.org/10.1002/..

9

Clinical Pharmacology of Brigatinib: A Next-Generation Anap..:

Gupta, Neeraj ; Hanley, Michael J. ; Griffin, Robert J....
Clinical Pharmacokinetics. 62 (2023) 8 - p. 1063-1079 , 2023

Link: https://doi.org/10.1007/..

10

Population pharmacokinetic/pharmacodynamic joint modeling o..:

Srimani, Jaydeep K. ; Diderichsen, Paul M. ; Hanley, Michael J....
CPT: Pharmacometrics & Systems Pharmacology. 11 (2022) 8 - p. 1085-1099 , 2022

Link: https://doi.org/10.1002/..

11

Mobocertinib Dose Rationale in Patients with Metastatic NSC..:

Gupta, Neeraj ; Largajolli, Anna ; Witjes, Han...
Clinical Pharmacology & Therapeutics. 112 (2022) 2 - p. 327-334 , 2022

Link: https://doi.org/10.1002/..

12

Pharmacometric analyses and clinical evidence for brigatini..:

Gupta, Neeraj ; Hanley, Michael J. ; Sinha, Vikram
British Journal of Clinical Pharmacology. 88 (2022) 8 - p. 3922-3923 , 2022

Link: https://doi.org/10.1111/..

13

Poster: ALL-049 A Phase 1/2 Study to Evaluate Ponatinib Wit..:

Gore, Lia ; Loh, Mignon ; Pui, Ching-Hon...
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S123 , 2022

Link: https://doi.org/10.1016/..

14

ALL-049 A Phase 1/2 Study to Evaluate Ponatinib With Chemot..:

Gore, Lia ; Loh, Mignon ; Pui, Ching-Hon...
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S190-S191 , 2022

Link: https://doi.org/10.1016/..

15

Population pharmacokinetic and exposure‐response analyses f..:

Gupta, Neeraj ; Reckamp, Karen L. ; Camidge, David R....
Clinical and Translational Science. 15 (2022) 5 - p. 1143-1154 , 2022

Link: https://doi.org/10.1111/..